Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA known ✓ | P10253 | 1/20 | 0.70 |
| ▸ | ESR2 known ✓ | Q92731 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.70 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.70 |
| ▸ | MEN1 | O00255 | 2/20 | 0.70 |
| ▸ | MAPT | P10636 | 2/20 | 0.70 |
| ▸ | THRB | P10828 | 2/20 | 0.70 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.70 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.70 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.70 |
| ▸ | RECQL | P46063 | 1/20 | 0.70 |
| ▸ | BLM | P54132 | 1/20 | 0.70 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.70 |
| ▸ | CYP3A4 | P08684 | 5/20 | 0.61 |
| ▸ | NPC1 | O15118 | 4/20 | 0.53 |
| ▸ | RAB9A | P51151 | 2/20 | 0.52 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.50 |
| ▸ | TRIM24 | O15164 | 1/20 | 0.50 |
| ▸ | TYR | P14679 | 1/20 | 0.50 |
| ▸ | TRIM33 | Q9UPN9 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL780305 | 0.98 | ALDH1A1 (0.67) | ALDH1A1TDP1MEN1MAPTTHRB | |
| Hydrochloric Acid SCHEMBL3020904 | 0.83 | ALDH1A1 (1.00) | ALDH1A1TDP1MEN1MAPTTHRB | |
| Hydrochloric Acid SCHEMBL10770715 | 0.82 | NR4A1 (0.58) | ALDH1A1TDP1MEN1MAPTTHRB | |
| SCHEMBL29878426 | 0.82 | CYP3A4 (0.65) | ALDH1A1TDP1MEN1MAPTTHRB | |
| SCHEMBL245052 | 0.80 | ALDH1A1 (0.96) | ALDH1A1TDP1MEN1MAPTTHRB | |
| Hydrochloric Acid SCHEMBL215131 | 0.79 | ALDH1A1 (0.68) | ALDH1A1TDP1MEN1MAPTTHRB | |
| Hydrochloric Acid SCHEMBL202563 | 0.79 | ALDH1A1 (0.68) | ALDH1A1TDP1MEN1MAPTTHRB | |
| Hydrochloric Acid SCHEMBL29524042 | 0.79 | ALDH1A1 (0.68) | ALDH1A1TDP1MEN1MAPTTHRB | |
| SCHEMBL30040301 | 0.79 | NR4A1 (0.61) | ALDH1A1TDP1MEN1MAPTTHRB | |
| SCHEMBL436522 | 0.79 | NR4A1 (0.61) | ALDH1A1TDP1MEN1MAPTTHRB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 79 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10907197-B2 | Probes for imaging huntingtin protein | CHDI FOUNDATION, INC. (US) | 2021-02-02 | — | — | US | disclosed |
| EP-3190888-B1 | PROBES FOR IMAGING HUNTINGTIN PROTEIN | CHDI FOUNDATION INC (US) | 2020-06-10 | — | — | EP | disclosed |
| US-10123978-B2 | Patch for treating dermatophytosis | MEIJI SEIKA PHARMA CO., LTD. (JP) | 2018-11-13 | — | — | US | disclosed |
| EP-2881114-B1 | ANTI-TRICHOPHYTIC ADHESIVE PATCH | MEIJI SEIKA PHARMA CO LTD (JP) | 2018-09-05 | — | — | EP | disclosed |
| US-20180200199-A1 | PATCH FOR TREATING DERMATOPHYTOSIS | MEIJI SEIKA PHARMA CO., LTD. (JP) | 2018-07-19 | — | — | US | disclosed |
| US-20170292150-A1 | PROBES FOR IMAGING HUNTINGTIN PROTEIN | CHDI FOUNDATION, INC. | 2017-10-12 | — | — | US | disclosed |
| EP-3190888-A1 | PROBES FOR IMAGING HUNTINGTIN PROTEIN | CHDI Foundation, Inc. (US) | 2017-07-19 | — | — | EP | disclosed |
| US-9447054-B2 | Anticancer supplement agent including benzo[D]oxazol derivative as effective ingredient | KOREA INSTITUTE OF RADIOLOGICAL & MEDICAL SCIENCES (KR) | 2016-09-20 | — | — | US | disclosed |
| US-20160101104-A1 | QUINUCLIDINE COMPOUNDS AS ALPHA-7 NICOTINIC ACETYLCHOLINE RECEPTOR LIGANDS | BRISTOL MYERS SQUIBB CO (US) | 2016-04-14 | — | — | US | disclosed |
| WO-2016033460-A1 | PROBES FOR IMAGING HUNTINGTIN PROTEIN | CHDI FOUNDATION, INC. (US) | 2016-03-03 | — | — | WO | disclosed |
| WO-2005040129-A2 | CCR3 RECEPTOR ANTAGONISTS | F. HOFFMANN-LA ROCHE AG (CH) | 2005-05-06 | — | — | WO | disclosed |
| US-20050090504-A1 | Piperidinyl and piperazinyl compounds substituted with bicyclo-heterocyclylalkyl groups useful as CCR3 receptor antagonists | ROCHE PALO ALTO LLC | 2005-04-28 | — | — | US | disclosed |
| EP-0621271-B1 | Benzoxazole derivatives and their use as serotonin 5-HT3 receptor antagonists | MEIJI SEIKA KAISHA (JP) | 2001-10-17 | — | — | EP | disclosed |
| US-5631257-A | ANTISEROTONIN AGENTS FOR TREATMENT OF NAUSEA AND ANTIEMETICS | MEIJI SEIKA KAISHA, LTD. (JP) | 1997-05-20 | — | — | US | disclosed |
| EP-0621271-A1 | Benzoxazole derivatives and their use as serotonin 5-HT3 receptor antagonists | MEIJI SEIKA KAISHA LTD. (JP) | 1994-10-26 | — | — | EP | disclosed |
| US-5273988-A | 2-(3,4,4,-trifluorobutenylmercapto) alkoxy or nitro benzoxazoyl compounds | IMPERIAL CHEMICAL INDUSTRIES PLC (GB) | 1993-12-28 | — | — | US | disclosed |
| EP-0532722-A1 | BENZOXAIOLE DERIVATIVES | ZENECA LIMITED (GB) | 1993-03-24 | — | — | EP | disclosed |
| WO-1992017463-A1 | BENZOXAIOLE DERIVATIVES | IMPERIAL CHEMICAL INDUSTRIES PLC (GB) | 1992-10-15 | — | — | WO | disclosed |
| EP-0507464-A1 | Benzoxazole derivatives | ZENECA LIMITED (GB) | 1992-10-07 | — | — | EP | disclosed |
| US-3996210-A | OPTICAL BRIGHTENERS | SANDOZ LTD. (CH) | 1976-12-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180200199-A1 | PATCH FOR TREATING DERMATOPHYTOSIS | DPM1, KRT18, LCP1 | GAA 4547/4885ESR2 3836/4885ALDH1A1 3414/4885 |
| US-10123978-B2 | Patch for treating dermatophytosis | DPM1, KRT18, LCP1 | GAA 4547/4885ESR2 3836/4885ALDH1A1 3414/4885 |
| US-10907197-B2 | Probes for imaging huntingtin protein | HTT, HYPK, FABP7 | GAA 706/4885ESR2 3717/4885ALDH1A1 3949/4885 |
| US-20160101104-A1 | QUINUCLIDINE COMPOUNDS AS ALPHA-7 NICOTINIC ACETYLCHOLINE RECEPTOR LIGANDS | CHRNA7, CHRNA5, CHRNA6 | GAA 446/4885ESR2 1228/4885ALDH1A1 1082/4885 |
| US-20050090504-A1 | Piperidinyl and piperazinyl compounds substituted with bicyclo-heterocyclylalkyl groups useful as CCR3 receptor antagonists | CCR9, CCR3, CCR1 | GAA 4865/4885ESR2 466/4885ALDH1A1 2336/4885 |
| US-20170292150-A1 | PROBES FOR IMAGING HUNTINGTIN PROTEIN | HTT, HYPK, FABP7 | GAA 706/4885ESR2 3717/4885ALDH1A1 3949/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.